Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (NEUPRODEX)

Trial Profile

Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (NEUPRODEX)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Cognition disorders; Delirium; Postoperative complications
  • Focus Therapeutic Use
  • Acronyms Neuprodex
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2018.
    • 21 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top